Trial Profile

A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE B10)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 22 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms KEYNOTE B10
Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

30 Jul 2024 Status changed from active, no longer recruiting to completed.
13 Sep 2022 Initial Results(n=92) presented at the 47th European Society for Medical Oncology Congress.
13 Sep 2022 According to the results presented at the 47th European Society for Medical Oncology Congress, at March 16, 2022, data cutoff, 92 of 100 planned pts were enrolled.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com